Tags

Type your tag names separated by a space and hit enter

Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study.
Am J Trop Med Hyg. 2020 02; 102(2):274-279.AJ

Abstract

Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL) are endemic diseases in America, especially in some countries such as Colombia. Among the therapeutic options is amphotericin B (AB). Nevertheless, its lipid-associated formulations have better safety profiles and effectiveness in other diseases, so far with no comparative studies in CL or MCL. We conducted a retrospective descriptive study describing the effectiveness and adverse effects of AB deoxycholate (ABD), AB colloidal dispersion (ABCD), and liposomal AB (LAB) as third-line treatments for CL and MCL. The effectiveness of LAB (88.5%) was greater than those of ABCD (66.6%) and ABD (80.8%). There were also fewer adverse effects in the LAB group (46.2%) than in the ABD (96.1%) and ABCD (80.9%) groups. LAB is an alternative for the treatment of CL and MCL in patients with therapeutic failure to first- and second-line drugs; findings suggest it might be less toxic and more effective than ABD and ABCD.

Authors+Show Affiliations

Central Military Hospital, Bogota, Colombia.Central Military Hospital, Bogota, Colombia.Nueva Granada Military University (Universidad Militar Nueva Granada), Bogota, Colombia.Central Military Hospital, Bogota, Colombia. Nueva Granada Military University (Universidad Militar Nueva Granada), Bogota, Colombia.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31820708

Citation

Rodríguez Galvis, María Claudia, et al. "Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: a Retrospective Study." The American Journal of Tropical Medicine and Hygiene, vol. 102, no. 2, 2020, pp. 274-279.
Rodríguez Galvis MC, Pérez Franco JE, Casas Vargas MY, et al. Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study. Am J Trop Med Hyg. 2020;102(2):274-279.
Rodríguez Galvis, M. C., Pérez Franco, J. E., Casas Vargas, M. Y., & Ordoñez Rubiano, M. F. (2020). Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study. The American Journal of Tropical Medicine and Hygiene, 102(2), 274-279. https://doi.org/10.4269/ajtmh.18-0514
Rodríguez Galvis MC, et al. Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: a Retrospective Study. Am J Trop Med Hyg. 2020;102(2):274-279. PubMed PMID: 31820708.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study. AU - Rodríguez Galvis,María Claudia, AU - Pérez Franco,Jairo Enrique, AU - Casas Vargas,Mirian Yolanda, AU - Ordoñez Rubiano,María Fernanda, PY - 2019/12/11/pubmed PY - 2020/5/16/medline PY - 2019/12/11/entrez SP - 274 EP - 279 JF - The American journal of tropical medicine and hygiene JO - Am J Trop Med Hyg VL - 102 IS - 2 N2 - Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL) are endemic diseases in America, especially in some countries such as Colombia. Among the therapeutic options is amphotericin B (AB). Nevertheless, its lipid-associated formulations have better safety profiles and effectiveness in other diseases, so far with no comparative studies in CL or MCL. We conducted a retrospective descriptive study describing the effectiveness and adverse effects of AB deoxycholate (ABD), AB colloidal dispersion (ABCD), and liposomal AB (LAB) as third-line treatments for CL and MCL. The effectiveness of LAB (88.5%) was greater than those of ABCD (66.6%) and ABD (80.8%). There were also fewer adverse effects in the LAB group (46.2%) than in the ABD (96.1%) and ABCD (80.9%) groups. LAB is an alternative for the treatment of CL and MCL in patients with therapeutic failure to first- and second-line drugs; findings suggest it might be less toxic and more effective than ABD and ABCD. SN - 1476-1645 UR - https://www.unboundmedicine.com/medline/citation/31820708/Effectiveness_and_Safety_of_Amphotericin_B_Deoxycholate_Amphotericin_B_Colloidal_Dispersion_and_Liposomal_Amphotericin_B_as_Third_Line_Treatments_for_Cutaneous_and_Mucocutaneous_Leishmaniasis:_A_Retrospective_Study_ L2 - https://ajtmh.org/doi/10.4269/ajtmh.18-0514 DB - PRIME DP - Unbound Medicine ER -